Skip to main content
Erschienen in: Clinical Rheumatology 9/2007

01.09.2007 | Brief Report

Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis

verfasst von: Alexandra Balbir-Gurman, Yolanda Braun-Moscovici, Vladimir Livshitz, Daniel Schapira, Doron Markovits, Alexander Rozin, Tatiana Boikaner, A. Menahem Nahir

Erschienen in: Clinical Rheumatology | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Oxidative stress is involved in pathogenesis of Raynaud’s phenomenon (RP), a hallmark of systemic sclerosis (SSc). Frequent episodes of ischemia–reperfusion may lead to release of free radicals and enhanced lipid peroxidation reflected by elevated levels of malondialdehyde (MDA). The failure of native antioxidants (Catalase [CAT], Superoxide dismutase [SOD], and Ceruloplasmin [CP]) might be crucial in endothelial cells damage in RP. Iloprost (IL) synthetic prostacyclin analogue is currently used in the treatment of SSc patients with RP. The objectives of this study were to compare the serum levels of MDA and CP, CAT and SOD activity in red blood cells hemolysate in SSc patients compared to healthy controls; and to study the effect of 5-days IL infusions on MDA and CP levels, and CAT and SOD activity in SSc patients with RP. Twelve SSc patients were treated with 50 μg IL for 5 days. Blood samples were taken before and after day 1st and after day 5th of IL infusions. Levels of CAT were measured according to the Aebi’s method; SOD, according to the Misra and Fridovich method; MDA, according to Slater’s method; and CP, according to Ravin’s method. Activities of CAT (p < 0.001) and SOD (p < 0.04) were significantly reduced; levels of CP (p < 0.006) and MDA (p < 0.06) were raised in SSc compared to controls. IL infusions caused reduction in MDA (p < 0.0001) levels and enhanced production of SOD (p < 0.006) and CAT (p < 0.003). The levels of CP did not change (p = 0.48). Oxidant status in SSc patients with RP is impaired. Therapy with IL led to normalization of antioxidant activity. We suggest that CAT may be a sensitive and reliable laboratory marker of oxidative stress severity in RP. We found that IL, in addition to its vasoactive properties, has a potential to activate inner antioxidant system. Activation of inner antioxidant activity may explain long-term effect of IL instead of its very short half-life time.
Literatur
1.
Zurück zum Zitat Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud’s phenomenon. Medicine (Baltimore) 59:393–408 Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud’s phenomenon. Medicine (Baltimore) 59:393–408
2.
Zurück zum Zitat Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28(1):78–85PubMedCrossRef Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28(1):78–85PubMedCrossRef
3.
Zurück zum Zitat Maxwell SR, Lip GY (1997) Reperfusion injury: a review of pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58(2):95–117PubMedCrossRef Maxwell SR, Lip GY (1997) Reperfusion injury: a review of pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58(2):95–117PubMedCrossRef
4.
Zurück zum Zitat Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206PubMed Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206PubMed
5.
Zurück zum Zitat Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581–590 Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581–590
6.
Zurück zum Zitat LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA et al (1988) Scleroderma (systemic sclerosis):classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA et al (1988) Scleroderma (systemic sclerosis):classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
7.
Zurück zum Zitat Ravin HA (1961) An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 58:161–168PubMed Ravin HA (1961) An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 58:161–168PubMed
8.
Zurück zum Zitat Aebi H (1974) Catalase. In: Bergmeyer U (ed) Methods of enzymatic analysis. Academic, NY, pp 673–677 Aebi H (1974) Catalase. In: Bergmeyer U (ed) Methods of enzymatic analysis. Academic, NY, pp 673–677
9.
Zurück zum Zitat Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3470–3475 Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3470–3475
10.
Zurück zum Zitat Slater TF, Sawyer BC (1971) The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 123(5):805–814PubMed Slater TF, Sawyer BC (1971) The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 123(5):805–814PubMed
11.
Zurück zum Zitat Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39(7):1146–1150PubMedCrossRef Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39(7):1146–1150PubMedCrossRef
12.
Zurück zum Zitat Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21(8):1477–1483PubMed Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21(8):1477–1483PubMed
13.
Zurück zum Zitat Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112(1):78–84PubMedCrossRef Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112(1):78–84PubMedCrossRef
14.
Zurück zum Zitat Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43(4):894–900PubMedCrossRef Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43(4):894–900PubMedCrossRef
15.
Zurück zum Zitat Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44(11):2653–2664PubMedCrossRef Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44(11):2653–2664PubMedCrossRef
16.
Zurück zum Zitat Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185(1):71–79PubMedCrossRef Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185(1):71–79PubMedCrossRef
17.
Zurück zum Zitat Rozen A, Casciola-Rozen L, Wigley F (1997) Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 9(6):538–543CrossRef Rozen A, Casciola-Rozen L, Wigley F (1997) Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 9(6):538–543CrossRef
18.
Zurück zum Zitat Musellim B, Ikitimur H, Uzun H, Ongen G (2006) The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int 27(2):163–167PubMedCrossRef Musellim B, Ikitimur H, Uzun H, Ongen G (2006) The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int 27(2):163–167PubMedCrossRef
19.
Zurück zum Zitat Tikly M, Channa K, Theodorou P, Gulimian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25(3):320–324PubMedCrossRef Tikly M, Channa K, Theodorou P, Gulimian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25(3):320–324PubMedCrossRef
20.
Zurück zum Zitat Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19(1):4–8PubMed Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19(1):4–8PubMed
21.
Zurück zum Zitat Das DK, Maulik KN, Moraru II (1995) Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol 27(1):181–193PubMedCrossRef Das DK, Maulik KN, Moraru II (1995) Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol 27(1):181–193PubMedCrossRef
22.
Zurück zum Zitat Tsan MF (1993) Superoxide dismutase and pulmonary oxygen toxicity. Proc Soc Exp Biol Med 203(3):286–290PubMed Tsan MF (1993) Superoxide dismutase and pulmonary oxygen toxicity. Proc Soc Exp Biol Med 203(3):286–290PubMed
23.
Zurück zum Zitat Pronai L, Arimoni S (1992) Decreased plasma superoxide scavenging activity in immunological disorders-carboxyethylgermanium sesquioxide (Ge-132) as a promoter of prednisolone. Biotherapy 1(4):1–8CrossRef Pronai L, Arimoni S (1992) Decreased plasma superoxide scavenging activity in immunological disorders-carboxyethylgermanium sesquioxide (Ge-132) as a promoter of prednisolone. Biotherapy 1(4):1–8CrossRef
24.
Zurück zum Zitat Morita A, Minami H, Sakakibara N, Sato K, Tsuji T (1996) Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 11(3):196–201PubMedCrossRef Morita A, Minami H, Sakakibara N, Sato K, Tsuji T (1996) Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 11(3):196–201PubMedCrossRef
25.
Zurück zum Zitat Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196(1–2):85–91PubMedCrossRef Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196(1–2):85–91PubMedCrossRef
26.
Zurück zum Zitat Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K (1999) Effect of superoxide dismutase on bleomycin induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 113(5):843–847PubMedCrossRef Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K (1999) Effect of superoxide dismutase on bleomycin induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 113(5):843–847PubMedCrossRef
27.
Zurück zum Zitat Mizushima Y, Hoshi K, Yanagawa A, Takano K (1991) Topical application of superoxide dismutase cream. Drugs Exp Clin Res 17(2):127–131PubMed Mizushima Y, Hoshi K, Yanagawa A, Takano K (1991) Topical application of superoxide dismutase cream. Drugs Exp Clin Res 17(2):127–131PubMed
28.
Zurück zum Zitat Niwa Y, Somiya K, Michelson AM, Puget K (1985) Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free Radic Res Commun 1(2):137–153PubMed Niwa Y, Somiya K, Michelson AM, Puget K (1985) Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free Radic Res Commun 1(2):137–153PubMed
29.
Zurück zum Zitat Jayson MI, Davis P, Whicher JT, Walters G (1975) Serum copper and caeruloplasmin in ankylosing spondylitis, systemic sclerosis, and morphea. Ann Rheum Dis 35(5):443–445PubMed Jayson MI, Davis P, Whicher JT, Walters G (1975) Serum copper and caeruloplasmin in ankylosing spondylitis, systemic sclerosis, and morphea. Ann Rheum Dis 35(5):443–445PubMed
30.
Zurück zum Zitat Mittag M, Beckheinrich P, Haustein UF (2001) Systemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81(4):294–297PubMedCrossRef Mittag M, Beckheinrich P, Haustein UF (2001) Systemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81(4):294–297PubMedCrossRef
31.
Zurück zum Zitat Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108(2):241–250PubMedCrossRef Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108(2):241–250PubMedCrossRef
32.
Zurück zum Zitat Mazzone A, Cusa C, Bucci L, Vezzoli M, Ghio S, Buggia I et al (1999) The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 29(1):1–5PubMedCrossRef Mazzone A, Cusa C, Bucci L, Vezzoli M, Ghio S, Buggia I et al (1999) The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 29(1):1–5PubMedCrossRef
Metadaten
Titel
Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis
verfasst von
Alexandra Balbir-Gurman
Yolanda Braun-Moscovici
Vladimir Livshitz
Daniel Schapira
Doron Markovits
Alexander Rozin
Tatiana Boikaner
A. Menahem Nahir
Publikationsdatum
01.09.2007
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 9/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0613-2

Weitere Artikel der Ausgabe 9/2007

Clinical Rheumatology 9/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.